Plain-English translation of NCT04008368 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is for people with sickle cell disease or beta-thalassemia who had a stem cell transplant before, but their disease symptoms have come back. Researchers want to give a second transplant using stem cells from the same donor to restore enough healthy donor cells in your blood to control the disease again. Early results suggest this approach can work when the first transplant's benefits fade over time.
Some patients who receive a stem cell transplant for these blood disorders see their symptoms return months or years later because the number of healthy donor cells in their blood drops too low. This trial is designed to see if a second transplant can safely restore those donor cells and keep the disease under control long-term.
You likely qualify if…
You likely don't qualify if…
You will receive a second transplant using stem cells donated by your original stem cell donor. Before the transplant, you will receive conditioning medications to prepare your body. After the transplant, you will be monitored closely with blood tests and clinic visits to track how well the new donor cells take hold and whether your disease symptoms improve. The trial will follow your progress to see if this approach safely restores disease control.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States